Nxera Pharma UK Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Heptares Therapeutics Limited (to 2024)
10
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for CGRP receptor antagonists (US 10,300,056) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 4 fees due Dec 11 to 25, 2026 · next Dec 11
- 2 fees due Jan 14 to 16, 2027 · next Jan 14
- 1 fee due Feb 20, 2027The maintenance fee for Bicyclic Aza Compounds as Muscarinic M1 Receptor And/Or M4 Receptor Antagonists (US 10,385,039) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Muscarinic M1 receptor agonists (US 10,413,553) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 4 fees due Apr 1 to 29, 2027 · next Apr 1
- 1 fee due May 17, 2027The maintenance fee for Muscarinic M1 receptor agonists (US 9,187,451) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.
- 1 fee due Jun 5, 2027The maintenance fee for Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists (US 11,834,407) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 6 fees due Aug 2 to 23, 2027 · next Aug 2
- 1 fee due Sep 10, 2027The maintenance fee for 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators (US 10,584,111) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
- 1 fee due Oct 2, 2027The maintenance fee for Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists (US 11,945,801) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 21, 2026
- Oct 27 US 12,774,289 H4 Antagonist Compounds
- Sep 8 US 12,729,189 GPR52 Modulator Compounds
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,915,303 | Glycopyrronium salts and their therapeutic use In force · USPTO record | In force | USPTO record | |
| US 11,673,938 | Mutant G-Protein Coupled Receptors and Methods for Selecting Them In force · Medium confidence | In force | Medium confidence | |
| US 9,260,505 | Methods for screening for binding partners of G-protein coupled receptors In force · USPTO record | In force | USPTO record | |
| US 10,126,313 | Methods for screening for binding partners of G-protein coupled receptors In force · USPTO record | In force | USPTO record | |
| US 9,081,020 | Mutant proteins and methods for selecting them In force · USPTO record | In force | USPTO record | |
| US 8,785,135 | Mutant G-protein coupled receptors and methods for selecting them In force · USPTO record | In force | USPTO record | |
| US 8,748,182 | Mutant proteins and methods for producing them In force · USPTO record | In force | USPTO record | |
| US 8,846,954 | Crystallisation and purification of glycopyrronium bromide In force · USPTO record | In force | USPTO record | |
| US 8,790,933 | Screening In force · USPTO record | In force | USPTO record | |
| US 8,703,915 | Mutant proteins and methods for producing them In force · USPTO record | In force | USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending